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Despite recent advances in catheter technology, acute com-
plications, including death, delayed abrupt closure and
periprocedural myocardial infarction, continue to occur in
10% to 15% of patients undergoing percutaneous coronary
intervention (PCI) (1,2). Because numerous observational
studies have now confirmed a close association between
ischemic complications of PCI and late mortality (3),
prevention of such complications remains a central goal of
the practicing interventional cardiologist. In recent years, it
has become increasingly clear that the coagulation cascade
plays a critical role in the pathogenesis of such complica-
tions (1,2,4,5). All forms of catheter-based revascularization
produce local endothelial injury, thus exposing underlying
tissue factor, which binds to and activates circulating Factor
VII (FVII). This activated form of FVII is then free to
activate other clotting factors (including Factors IX and X),
thus leading to the generation of thrombin, platelet activa-
tion and, ultimately, to the formation of thrombus at the site
of the catheter-induced arterial injury.
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Following from this model, one might postulate that the
risk of subacute ischemic complications after catheter-
induced endothelial injury should be influenced by circulat-
ing levels of FVII. In theory, higher levels of circulating
FVII should increase the risk of an ischemic complication,
while lower levels of circulating FVII would be protective.
Recently, several genetic polymorphisms that influence
FVII levels have been identified, including an A10,976 G
point mutation on exon 8 of the FVII gene that leads to a
substitution of glutamine for arginine at codon 253 (Arg253
Gln polymorphism) (6). In the Framingham Heart Study,
this mutation was shown to lead to a dose-dependent
decrease in FVII activity (7). It is conceivable, therefore,
that persons who have one or two copies of this allele might
be at lower risk of ischemic complications after PCI.
In this issue of the Journal, Mrozikiewicz et al. (8)
describe the results of a preliminary study to test this
hypothesis. In a cohort of 666 consecutive patients under-
going PCI at a single center, ischemic complications,
including death, myocardial infarction, or repeat target
vessel revascularization within 30 days, occurred in 6.4% of
patients. Although most traditional clinical and angio-
graphic factors failed to predict the occurrence of these
complications, they found that patients who were either
heterozygous or homozygous for the Arg253Gln polymor-
phism had a substantially reduced risk of ischemic compli-
cations after PCI, compared with patients without this
polymorphism. This effect seemed to be fairly consistent
regardless of the type of PCI employed (balloon angioplasty,
directional atherectomy or stenting) and persisted after
adjustment for a variety of clinical and angiographic factors
previously shown to predict such complications. The au-
thors conclude, therefore, that activated FVII is important
in the pathogenesis of ischemic complications after PCI and
suggest that pharmacologic therapy directed at inhibiting
activated FVII during PCI may be a useful approach for
further reducing the incidence of such complications.
Although these findings are interesting and of potential
pathophysiologic and therapeutic relevance, the main value
of this study is in highlighting many of the principles of
genomic epidemiology that are becoming increasingly im-
portant techniques for biomedical research. Complex
genomic association analysis, of which this study is an
example, is dedicated to discovering alleles and genotypes
that are associated with various common clinical outcomes.
Identifying and understanding these associations is likely to
fundamentally change our basic understanding of cardiovas-
cular disease, and this study illustrates several ways in which
genomics is likely to influence cardiovascular medicine.
The study by Mrozikiewicz et al. (8) clearly illustrates
that, unlike simple monogenic or Mendelian disorders, even
genotypes that have an apparently profound effect on a
common complex disease actually have only a very small
absolute effect. When expressed as the reciprocal of the
absolute risk difference, the magnitude of a complex genetic
association can be thought of as the number needed for genetic
effect (NNGE) (9). The NNGE is the number of persons
with a particular genotype who are likely to experience the
associated disease as the result of the specific genetic effect. For
example, in this study, individuals with the Arg253/Arg253
genotype had an approximately three times greater risk for
ischemic complications following PCI relative to individuals
with at least one Arg253Gln allele (relative risk 5 7.7%/2.5%
5 3.1). By contrast, when expressed as the reciprocal of the
absolute risk difference, the NNGE is 19.2 (i.e., 1/[0.077 2
0.025]). These same data thus indicate that despite a
substantially increased relative risk, only one of every 19
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individuals with the Arg253/Arg253 genotype will experience
an ischemic complication of PCI as the result of a genetic
effect.
This concept is important because it illustrates that,
contrary to popular expectation, most genotypes associated
with common complex cardiovascular diseases are not likely
to be determinative, or even particularly predictive. Only a
small fraction of individuals who inherit a genotype associ-
ated with a common cardiovascular disease are likely to
ultimately develop the disease as the result of a genetic effect.
Instead, complex genomic associations are much more likely
to help cardiologists identify subgroups of patients who are
at various levels of risk based on their genotype, and to help
physicians choose treatment strategies that are most appro-
priate to a particular patient’s genomic profile.
Furthermore, elucidating the various genetic pathways
that may contribute to a common clinical outcome is likely
to reveal that most common cardiovascular events, such as
ischemic complications of PCI, are actually the common
manifestation of diverse genetic influences. Appreciation of
the different genetic etiologies of common clinical events
will reduce the heterogeneity inherent in any complex
genetic disease and allow physicians to choose more rational
individualized primary and secondary prevention treatment
strategies based on genotype. For example, in the example
provided by this study, perhaps only persons with the
Arg253/Arg253 genotype will benefit from activated FVII
inhibition during PCI, or perhaps optimal dosing may
depend on FVII genotype. Elucidation of these genetic
pathways will not only improve our understanding of how
and why disease develops but it will also ultimately suggest
novel treatment strategies to interrupt the disease process.
Clearly, genomics has the potential to profoundly impact
cardiovascular medicine. With the completion of the Hu-
man Genome Project imminent, the number of clinical
genomic epidemiologic studies is likely to increase substan-
tially. Because its potential influence is so great, the cardio-
vascular community must demand that these studies be
conducted with the most rigorous methodologies and be
subjected to the most critical scrutiny prior to being pub-
lished. Unfortunately, the study by Mrozikiewicz et al. (8)
in this issue of the Journal, not unlike many genomic
epidemiologic studies, fails to adhere to several basic prin-
ciples of epidemiologic science. Thus, the results of this
study must be interpreted with considerable caution.
The most obvious deficiency in this study is the fact that
the authors do not mention, nor did they specifically
attempt to control for population stratification bias, the single
most important bias peculiar to genomic epidemiology (10).
Comparing the genotypes of unrelated persons with and
without a particular clinical outcome, such as ischemic
complications following PCI, is a deceptively simple study
design. Without adequate sampling restrictions, however,
this design can easily lead to spurious genetic associations.
Population stratification bias consists of two independent
components, confounding and sampling bias, either or both
of which can occur in a genetic case-control study. The
overall impact of this bias is equal to the effect of the
confounding bias multiplied by the effect of the sampling
bias, and either component bias alone, or the combined
effect of both biases, can cause a spurious genetic associa-
tion.
Both components of population stratification bias are
caused by the presence of distinct genetic subgroups within
the assembled study sample. These genetic subgroups are
sometimes difficult to detect, but they are usually present
within most unrestricted sampling frames. Therefore, the
most important feature of any genomic epidemiologic study
is that it must specifically attempt to control for the possible
effect of population stratification bias by restricting the
sampling frame.
The sampling bias component of population stratification
is caused by sampling affected and unaffected persons from
different genetically admixed populations. It can be elimi-
nated by sampling all affected and unaffected persons from
the same enumerated population of eligible subjects. This
sampling strategy ensures that the case and control subjects
will have comparable genetic backgrounds. Fortunately, the
cohort design employed by Mrozikiewicz et al. (8) accom-
plishes this goal because all affected and unaffected persons
are derived from the same cohort of the 666 consecutive
patients undergoing PCI. Therefore, sampling bias due to
population stratification is not likely to have affected the
results of this study.
The confounding bias component of population stratifi-
cation is caused by the presence of distinct genetic sub-
groups within the study population, even when both the
case and control subjects are derived from the same source
population. If these genetic subgroups have both a different
frequency of the genotype under study and a different rate of
the outcome event in interest, then an epidemiologic con-
founding bias will be present. This bias can be largely
eliminated by further restricting the study to a few self-
identified subgroups within a single main ethnic group. The
potential for confounding bias due to population stratifica-
tion can then be eliminated by stratifying the genetic
analysis by subgroup. These calculations can be efficiently
performed using stratified logistic regression analysis, in
which outcome is the dependent variable, genotype is the
independent variable, and ethnic subgroup is the stratifying
variable. Unfortunately, the authors of the current study did
not attempt to explicitly take into account the genetic origin
of the persons enrolled in their study. Therefore, confound-
ing due to population stratification bias cannot be excluded
as a possible explanation for their results.
In addition to the potential for bias, it is also important to
consider the possibility that chance alone explains the results
of this study. In general, relatively small studies such as this
(with only 46 outcome events) should be viewed as
hypothesis-generating, at best, because the temptation to
test hundreds of genetic polymorphisms in the same cohort
is too great. Using a nominal significance level of p , 0.05,
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one can expect that many of these polymorphisms will be
regarded as “statistically significantly” associated with a
common disease merely by chance. In addition, small
sample sizes do not permit the investigators to evaluate the
increasingly clinically pertinent topic of gene by gene, and
gene by environment, interactions. It is curious that in the
study by Mrozikiewicz et al. (8), the level of FVII activity in
those persons with an Arg253Gln allele who suffered an
ischemic complication was the same as the FVII activity
among persons with the Arg253/Arg253 genotype who ex-
perienced such an event. This observation strongly suggests
the possibility that some environmental factor may have
been interacting with the Arg253Gln allele to modify its
effect on FVII activity in exposed persons and, therefore,
modified their risk of ischemic complications. Unfortu-
nately, this possibility cannot be evaluated, because the
study was not large enough to detect and characterize such
a potentially clinically pertinent gene by environment inter-
action.
Considering these important limitations, what have we
learned from this study? We have learned that aspects of the
coagulation cascade, in addition to the platelet, may play an
important role in the pathogenesis of ischemic complica-
tions of PCI. In the future, novel anticoagulant strategies
directed specifically against activated FVII or the FVII-
tissue factor interaction may be an important adjunct to our
pharmacologic armamentarium for PCI patients. Moreover,
we have identified a relatively common genetic polymor-
phism (the Arg253Gln polymorphism) that may be protec-
tive against ischemic complications in PCI. If this associa-
tion is confirmed in other studies and a simple genetic
screen is developed for this polymorphism, it might be
possible to tailor a patient’s treatment to his or her specific
risks of complications. For now, however, these conclusions
are highly preliminary and await confirmation by larger,
prospective studies.
The caveats outlined above notwithstanding, Mrozik-
iewicz et al. (8) should be congratulated for performing an
intriguing study that illustrates both the potential and the
limitations of genomic medicine. Perhaps the most impor-
tant contribution of this study, however, is to point out that
there is an urgent need for a closer collaboration among
geneticists, epidemiologists and clinical scientists in order to
improve the quality of genomic epidemiologic research.
Editors, reviewers and readers of cardiovascular journals
must demand that elegant molecular genetic methods be
accompanied by rigorous epidemiologic methods. Because
the potential impact of genomics is so great, the cardiovas-
cular medicine community should demand more, not fewer,
such studies. We should, however, also demand that such
studies be large enough to draw firm conclusions and
rigorous enough to persuade us that genomic information
can make important contributions to the practice of cardio-
vascular medicine.
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